Catalyst + Talent. Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. With over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results.
Catalent develops. With our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products.
Catalent delivers. As the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments.
Catalent supplies. Globally positioned to serve all your manufacturing and commercial packaging needs, we provide integrated solutions to take your product from design, to clinical trial, to plant, and to pharmacy.
Catalent. More products. Better treatments. Reliably supplied.™

Show more
Type
Public
HQ
Franklin Township, US
Founded
2007
Size (employees)
10,800 (est)
Catalent was founded in 2007 and is headquartered in Franklin Township, US
Report incorrect company information

Catalent Office Locations

Catalent has offices in Singapore, Franklin Township, Braeside, Kakegawa and in 28 other locations
Franklin Township, US (HQ)
14 Schoolhouse Rd
Show all (32)
Report incorrect company information

Catalent Financials and Metrics

Catalent Revenue

Embed Graph
Catalent's revenue was reported to be $1.85 b in FY, 2016 which is a 0.9% increase from the previous period.
USD

Market capitalization (16-Aug-2018)

5.9 b

Closing stock price (16-Aug-2018)

40.8
Catalent's current market capitalization is $5.9 b.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

1.8 b1.8 b1.8 b

Revenue growth, %

0%1%

Cost of goods sold

1.2 b1.2 b1.3 b

Gross profit

598.6 m615.3 m587.6 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

418.3 m455.8 m446.6 m423 m454.9 m438 m442.2 m483.7 m532.6 m543.9 m

Cost of goods sold

293 m299.7 m294.4 m301.5 m302.8 m311.8 m318.1 m335.8 m365.2 m403.8 m

Gross profit

125.3 m156.1 m152.2 m121.5 m152.1 m126.2 m124.1 m147.9 m167.4 m140.1 m

Gross profit Margin, %

30%34%34%29%33%29%28%31%31%26%
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

74.4 m151.3 m131.6 m

Accounts Receivable

403.7 m372.4 m414.8 m

Inventories

134.8 m132.9 m154.8 m

Current Assets

687.5 m737.5 m790.2 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

63.2 m84.1 m116.1 m151.4 m132.1 m255.8 m241.2 m601.4 m

Accounts Receivable

332.2 m336.4 m331.6 m308.2 m332 m343.7 m376.3 m366.3 m402.6 m410.5 m

Inventories

142.4 m144.3 m142.2 m150.9 m159.3 m167.7 m177.5 m169.8 m193.9 m194 m

Current Assets

619.1 m637.5 m653.1 m691.2 m679.5 m727.5 m768.9 m882.6 m928.4 m1.3 b
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

15.2 m210.3 m111.2 m

Depreciation and Amortization

142.9 m140.8 m140.6 m

Cash From Operating Activities

178.3 m171.8 m155.3 m

Cash From Investing Activities

(171.2 m)(271.8 m)(137.7 m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

39.5 m49.3 m4.6 m22 m26 m3.8 m

Depreciation and Amortization

35 m70.2 m104.6 m35.5 m70.7 m105.5 m35.8 m71.3 m107.8 m

Inventories

194 m

Accounts Payable

166.8 m
Show all financial metrics

Catalent Operating Metrics

Catalent's Backlog was reported to be 827.5m in FY, 2016.
FY, 2015FY, 2016

Backlog

827.60 m827.50 m

Countries

80

Facilities

33

Patents Issued

1.10 k
Show all operating metrics

Catalent Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Juniper Pharmaceuticals July 02, 2018$128 m

Catalent Revenue Breakdown

Embed Graph

Catalent revenue breakdown by business segment: 16.3% from Clinical Supply Services, 42.7% from Drug Delivery Solutions and 41.0% from Softgel Technologies

Report incorrect company information

Catalent Online and Social Media Presence

Embed Graph
Report incorrect company information

Catalent News and Updates

Clinical Trial 2018 Global Market Key Players - Patheon, Parexel International, Sharp Packaging Services, ALMAC Group, Catalent Pharma Solutions.....

Clinical Trial – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

Catalent to buy Juniper Pharmaceuticals for $11.50 per share

July 3 (Reuters) - U.S. drug contract manufacturer Catalent Inc said on Tuesday it will buy Juniper Pharmaceuticals Inc for $11.50 per share in cash.

Biologics Market 2018; Gains to Spell Spectacular Growth of 8.6% CAGR with Renowned Players | By Type Vaccines, Blood Products, Gene Therapy, etc. – Says MRFR

According To a Recent Report Published by Market Research Future, Titled “Biologics Market” By Type (Vaccines, Blood Products, Proteins, Gene Therapy, Other), By Application (Anemia, Cancer, Diabetes And Other), By Source (Human, Animal And Microorganism). The report provides a comprehensive analysi…

Blow Fill Seal Technology Market Estimated to Exhibit 8.7% CAGR through 2027

Blow Fill Seal Technology Market Estimated to Exhibit 8.7% CAGR through 2027 Posted via Industry Today. Follow us on Twitter @IndustryToday

Specialty Oils Market Trend, Top Key Players Update, Industry Growth, Future Scope, Demand and In-depth Analysis Research Report by Forecast to 2022

Specialty Oils Market - by Source (Avocado, Hazelnut, Pistachio, Almond), process type (Hot pressed, Cold pressed and others), Application (Salad dressing, Sauce, Dips) and Region - Forecast to 2022 Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more
Report incorrect company information

Catalent Company Life and Culture

Report incorrect company information